![logo](/logos/EXEL.webp)
Exelixis, Inc.
NASDAQ:EXEL
25.15 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Exelixis, Inc. |
Symbool | EXEL |
Munteenheid | USD |
Prijs | 25.15 |
Beurswaarde | 7,174,087,800 |
Dividendpercentage | 0% |
52-weken bereik | 18.64 - 27.53 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michael M. Morrissey Ph.D. |
Website | https://www.exelixis.com |
An error occurred while fetching data.
Over Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)